Researchers are recruiting for a randomized, double-blinded phase III trial to assess the efficacy and tolerability of fulvestrant (Faslodex) injection. The Evaluation of Faslodex vs. Exemestane Clinical Trial aims to enroll 660 postmenopausal women with hormone receptor--positive metastatic breast cancer in the U.S. and worldwide. Contact AstraZeneca, 866-992-9276.
COPYRIGHT 2003 International Medical News Group
COPYRIGHT 2003 Gale Group